The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.
Hosted on MSN11h
Top Analyst Reports for UnitedHealth, Bank of America & SAPDupixent to Remain Sanofi's (SNY) Key Top-Line Driver The Zacks analyst expects Dupixent to remain Sanofi's key top-line driver as it enjoys strong demand trends. Sanofi has also accelerated its ...
A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Patients had been previously treated with Dupixent with little success. However, the results of this latest Ebglyss study ...
Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback